Le Lézard
Classified in: Health
Subjects: MAV, CFG

/R E P E A T -- NOTICE TO THE MEDIA - Government of Canada to make announcement regarding the mental health crisis and suicide prevention support/


BRAMPTON, ON, Nov. 8, 2023 /CNW/ - The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will make an important announcement on the mental health crisis and suicide prevention support.

There will be a media availability immediately following the announcement.

Date
November 9, 2023

Time
2 p.m (EST)

Location

The event will be held in-person at:

Grace Place
156 Main Street North
2nd Floor
Brampton, Ontario
L6V 1N9

Media may also join by Zoom:

https://hc-sc-gc-ca.zoom.us/j/61876564444
Passcode: 896418

Please indicate your name (first and last) and media outlet when joining the event.

SOURCE Health Canada (HC)


These press releases may also interest you

at 23:11
TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up...

at 23:00
Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue of RMB 2.7 billion, representing an 11.2%...

at 21:03
As the demand for surgical precision and faster patient recovery continues to grow, smart healthcare has achieved another major breakthrough. Since 2006, Chang Gung Memorial Hospital has pioneered the use of the Da Vinci Robotic Surgical Systems. By...

at 20:30
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been...

at 20:15
CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab....

at 20:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: